Business
Go Epic Health Updates on Cholesterade® Case Studies and Clinical Research
Go Epic Health Updates on Cholesterade® Case Studies and Clinical Research.
About this update from Leone Asset Management, Inc.
[{"type":"text","content":"\nSt. Petersburg, FL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Today, Leone Asset Management (OTC PINK: LEON) announced their subsidiary Go Epic Health is commencing additional Case Studies and Clinical Research on their all-natural cholesterol lowering product Cholesterade®.\n James Price, CEO of Go Epic Health, stated, “We are extremely excited to update our shareholders and the general public about additional studies being performed to show the efficacy of Cholesterade® for cholesterol reduction.”   Cholesterade® was originally created by the late Dr. J. Robert Cade, the inventor of Gatorade®, to lower his cholesterol levels.  Dr. Cade was taking statin drugs for the problem but suffered from major side effects from the use.  Therefore, he decided to create an all-natural alternative.  Once created, Dr. Cade performed an initial case study and found the results to be amazing amongst the group.  Without making any other lifestyle changes study participants saw a reduction in triglycerides of 50%, a reduction of bad cholesterol or LDL of 21.3% and a rise of good cholesterol or HDL of 12.9% in an 8-week period. To further prove the efficacy of the product, Go Epic Health engaged Dr. Richard Goldfarb to complete a new proof of concept study.  Prior to the study, we made a couple of minor improvements to the original formula by adding a specific and proprietary enzyme blend as well as an all-natural and patent pending delivery system to improve the efficacy of the product.  In the same 8-week period, Dr. Goldfarb found improved results due to the enhanced formula.  In this study, participants saw a reduction in bad cholesterol or LDL of 25% and increase in good cholesterol or HDL of 13% and a reduction in Triglycerides of 53%.  Price continued, “As any prudent company would do, we are completing additional and multiple studies within different study groups to prove not only short-term results but the long-term benefits of Cholesterade® with in different types of participants. “The first of our new studies has been filed with WIRB (study number 1188721).  This is a multi-center double blind study to test the lipid lowering effects and Cardiovascular benefits of Cholesterade® on a long-term basis with quarterly result...